Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (122)

2024

  1. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

    The Lancet, Vol. 404, Núm. 10459, pp. 1227-1239

  2. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204

  3. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

  4. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  5. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

    Lung Cancer, Vol. 192

  6. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma

    Leukemia and Lymphoma, Vol. 65, Núm. 3, pp. 323-332

  7. Developing Therapies for C3 Glomerulopathy Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group

    Clinical Journal of the American Society of Nephrology, Vol. 19, Núm. 9, pp. 1201-1208

  8. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

  9. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

    Pharmacological Research, Vol. 200

2023

  1. Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children

    Clinical and Translational Science, Vol. 16, Núm. 3, pp. 478-488

  2. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  3. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  4. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 115-124

  5. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072

  6. Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response

    Liver International, Vol. 43, Núm. 9, pp. 1984-1994

  7. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 4, pp. 1134-1146

  8. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey

    BMJ Open, Vol. 13, Núm. 3

  9. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 5, pp. 1004-1016

  10. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

    Clinical Trials, Vol. 20, Núm. 1, pp. 13-21

2022

  1. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

    Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634